Maximilian Merz,Efrat Luttwak
Maximilian Merz
Vasu and colleagues report one of the first clinical evaluations of rapidly manufactured trispecific chimeric antigen receptor T cells targeting CD19, CD20, and CD22. The lymphoma efficacy signal and favorable observed safety profile suppor...
Laura Evgin,Christian Steidl
Laura Evgin
In this issue of Blood Cancer Discovery, Yang and colleagues present a comprehensive repository of patient-derived xenograft models of aggressive large B-cell lymphoma. The publicly available resource links disease specimens from individual...
LY3410738, a Covalent Inhibitor of Mutant IDH1/2, is Effective in Acute Myeloid Leukemia Preclinical Models [0.03%]
LY3410738（一种针对IDH1/2突变体的共价抑制剂）在急性髓系白血病的临床前模型中有效
Nathan A Brooks,Anna Skwarska,Vivian Salama et al.
Nathan A Brooks et al.
Acute myeloid leukemia (AML) is an aggressive blood disorder characterized by rapid growth of poorly differentiated myeloid cells. Gain-of-function mutations in isocitrate dehydrogenases (IDHs) are detected in ~20% of AML and ~80% of second...
The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem Cells [0.03%]
烟酸补救途径是高危MDS干细胞的代谢弱点路径
Sweta B Patel,Daniel R Moskop,Steven Moreira et al.
Sweta B Patel et al.
High-risk myelodysplastic syndrome (HR-MDS) is a malignant clonal disorder originating in hematopoietic stem and progenitor cells (HSPCs). The current standard of care for HR-MDS patients has a poor response, thus necessitating exploration ...
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22 [0.03%]
针对CD19、CD20和CD22的三特异性CAR-T细胞首次人体试验的安全性和临床结果：点对点生产的临床试验
Sumithira Vasu,Nathan Denlinger,No-Joon Song et al.
Sumithira Vasu et al.
Disease recurrence is the main cause of treatment failure after CD19-directed CAR T cells, often due to CD19 antigen loss, stability and/or coverage. To overcome single-antigen escape, we evaluated a trispecific CAR targeting CD19, CD20, an...
Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid Malignancies [0.03%]
遗传突变和表观遗传沉默驱动CD7 CAR-T治疗后T细胞淋巴瘤抗原阴性复发
Rongrong Chen,Haiqiong Zheng,Wenxin Wang et al.
Rongrong Chen et al.
CD7 is a promising target for chimeric antigen receptor (CAR) T-cell therapy in T-cell lymphoid malignancies; however, antigen loss-mediated relapse emerged as a major challenge. Herein, we systematically analyzed the genetic and epigenetic...
BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules? [0.03%]
淋巴瘤中的BTK降解剂：新方法，新的耐药规则？
Alberto J Arribas,Carlo Visco,Francesco Bertoni
Alberto J Arribas
After more than a decade of clinical experience with BTK inhibitors, resistance to BTK targeting has become a moving target, shaped by drug-specific BTK mutations, downstream signaling escape, and disease-dependent adaptive programs. The ar...
Tumor-infiltrating clonal hematopoiesis is associated with adverse clinical outcomes in diffuse large B-cell lymphoma [0.03%]
肿瘤浸润性克隆型造血功能与弥漫性大B细胞淋巴瘤不良临床结局相关
Jiahao Chen,Xiao-Yu Wu,Xiang Li et al.
Jiahao Chen et al.
Tumor-infiltrating clonal hematopoiesis (TI-CH) contributes to progression of non-hematologic cancers. CH is prevalent in peripheral blood of patients with diffuse large B-cell lymphoma (DLBCL), but TI-CH prevalence and clinical relevance r...
Beyond Static Subtypes in Large B-cell Lymphoma: Context, Plasticity, and Therapeutic Logic [0.03%]
超越大B细胞淋巴瘤中的静态亚型：背景、可塑性和治疗逻辑
Laura K Hilton,Christopher R Flowers,Jean L Koff
Laura K Hilton
Although genomic classifiers have provided unprecedented insights into the biology of large B-cell lymphoma (LBCL), their ability to consistently predict outcomes across diverse patient populations and therapeutic contexts remains limited. ...
A Patient-Derived Xenograft Repository Capturing Clinical and Molecular Heterogeneity of Large B-cell Lymphoma [0.03%]
一种包含弥漫性大B细胞淋巴瘤临床和分子异质性的患者来源异种移植库
Haopeng Yang,Kotaro Arita,Kevin Bowman et al.
Haopeng Yang et al.
Large B-cell lymphomas (LBCL) are a clinically and molecularly diverse group of malignancies with a rapidly evolving therapeutic landscape that has introduced new areas of clinical need, such as post-CD19 chimeric antigen receptor T (CART19...